PMID- 38165516
OWN - NLM
STAT- MEDLINE
DCOM- 20240325
LR  - 20240325
IS  - 2210-7711 (Electronic)
VI  - 46
IP  - 2
DP  - 2024 Apr
TI  - Evaluating the impact of PD-1 inhibitor treatment on key health outcomes for 
      cancer patients in China.
PG  - 429-438
LID - 10.1007/s11096-023-01675-w [doi]
AB  - BACKGROUND: There is a lack of studies examining the influence of programmed cell 
      death protein 1 (PD-1) inhibitors on the health outcomes of cancer patients in 
      China. AIM: This study aimed to evaluate prospective health outcomes associated 
      with introducing PD-1 inhibitor treatment in China over five years. METHOD: We 
      constructed a partitioned survival model to assess disparities in health outcomes 
      over a 5-year time frame between two scenarios: one involving the availability of 
      PD-1 inhibitor class with standard of care and the other involving standard of 
      care alone. The impact on various health outcomes were assessed, including life 
      years (LYs) gained, quality-adjusted life years (QALYs) gained, progression-free 
      survival (PFS) years gained, the reduction in the number of grade 3-5 adverse 
      events (AEs), and the improvement in objective remission rates (ORR). A 
      sensitivity analysis was conducted to assess the robustness and reliability of 
      the model. RESULTS: From 2023 to 2027, the incorporation of PD-1 inhibitor class 
      treatments was anticipated to yield substantial improvements in health outcomes, 
      with an estimated increase of 1,336,332 LYs (+ 24.7%), 1,065,359 QALYs (+ 30.3%), 
      and 1,177,564 PFS years (+ 57.4%) compared to standard of care alone. 
      Simultaneously, the number of grade 3-5 AEs decreased by 334,976 (- 13.0%), and 
      the ORR saw a 19.1% increase (+ 105.6%) relative to standard of care treatment 
      alone. CONCLUSION: This study provides a analysis of the potential beneficial 
      effects on health outcomes in the Chinese population after introducing PD-1 
      inhibitor class treatment. The findings suggest the PD-1 inhibitor class will 
      significantly improve patient survival.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
FAU - Zhang, Pei
AU  - Zhang P
AD  - Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of 
      Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
FAU - Zhang, Lingli
AU  - Zhang L
AD  - Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of 
      Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
FAU - Xu, Kai
AU  - Xu K
AD  - Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of 
      Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
FAU - Lin, Yingtao
AU  - Lin Y
AD  - Department of Drug Clinical Trial Institution, Fujian Cancer Hospital, Fuzhou, 
      350014, China.
AD  - Center for Global Health, School of Public Health, Nanjing Medical University, 
      Nanjing, 211166, China.
FAU - Ma, Rui
AU  - Ma R
AD  - Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of 
      Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
FAU - Zhang, Mengdie
AU  - Zhang M
AD  - Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of 
      Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
FAU - Li, Xin
AU  - Li X
AUID- ORCID: 0000-0003-3951-8061
AD  - Department of Pharmaceutical Regulatory Science and Pharmacoeconomics, School of 
      Pharmacy, Nanjing Medical University, Nanjing, 211166, China. xinli@njmu.edu.cn.
AD  - Center for Global Health, School of Public Health, Nanjing Medical University, 
      Nanjing, 211166, China. xinli@njmu.edu.cn.
LA  - eng
GR  - 72074123/National Natural Science Foundation of China/
GR  - 72304150/National Natural Science Foundation of China/
PT  - Journal Article
DEP - 20240102
PL  - Netherlands
TA  - Int J Clin Pharm
JT  - International journal of clinical pharmacy
JID - 101554912
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Humans
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - Reproducibility of Results
MH  - *Neoplasms/drug therapy/epidemiology
MH  - Outcome Assessment, Health Care
MH  - China/epidemiology
MH  - *Lung Neoplasms/drug therapy
OTO - NOTNLM
OT  - Health outcomes
OT  - Immuno-oncology
OT  - PD-1 inhibitors
OT  - Partitioned survival model
EDAT- 2024/01/02 12:42
MHDA- 2024/03/25 06:43
CRDT- 2024/01/02 11:09
PHST- 2023/10/04 00:00 [received]
PHST- 2023/11/19 00:00 [accepted]
PHST- 2024/03/25 06:43 [medline]
PHST- 2024/01/02 12:42 [pubmed]
PHST- 2024/01/02 11:09 [entrez]
AID - 10.1007/s11096-023-01675-w [pii]
AID - 10.1007/s11096-023-01675-w [doi]
PST - ppublish
SO  - Int J Clin Pharm. 2024 Apr;46(2):429-438. doi: 10.1007/s11096-023-01675-w. Epub 
      2024 Jan 2.